The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA
Open accessAbstract
Guidelines regarding recommendations for PSA screening for early detection of prostate cancer are conflicting. In 2012, the United States Preventive Services Task Force (USPSTF) assigned a grade of D (recommending against screening) for men aged ≥75 years in 2008 and for men of all ages in 2012. Understanding temporal trends in rates of screening before and after the 2012 recommendation in terms of usage patterns in PSA screening, changes in prostate cancer incidence and biopsy patterns, and how the recommendation has influenced physician's and men's attitudes about PSA screening and subsequent ordering of other screening tests is essential within the scope of prostate cancer screening policy. Since the 2012 recommendation, rates of PSA screening decreased by 3–10% in all age groups and across most geographical regions of the USA. Rates of prostate biopsy and prostate cancer incidence have declined in unison, with a shift towards tumours being of higher grade and stage upon detection. Despite the recommendation, some physicians report ongoing willingness to screen appropriately selected men, and many men report intending to continue to ask for the PSA test from their physician. In the coming years, we expect to have an improved understanding of whether these decreased rates of screening will affect prostate cancer metastasis and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Légaré, F., & Witteman, H. O. (2013) · Health Affairs · doi:10.1377/hlthaff.2012.1078 · Cited by 783
Cited by
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Cancer health disparities in racial/ethnic minorities in the United States
Zavala, V. A., Bracci, P. M., Carethers, J. M., Carvajal-Carmona, L., Coggins, N. B., Cruz-Correa, M. R., Davis, M., de Smith, A. J., Dutil, J., Figueiredo, J. C., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01038-6 · Cited by 912
Multiparametric MRI for prostate cancer diagnosis: current status and future directions
Stabile, A., Giganti, F., Rosenkrantz, A. B., Taneja, S. S., Villeirs, G., Gill, I. S., Allen, C., Emberton, M., Moore, C. M., & Kasivisvanathan, V. (2020) · Nature Reviews Urology · doi:10.1038/s41585-019-0212-4 · Cited by 398
Cancer Screening and Early Detection in the 21st Century
Loud, J. T., & Murphy, J. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.02.002 · Cited by 289
miRNAs as therapeutic tools and biomarkers for prostate cancer
Arrighetti, N., & Beretta, G. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030380 · Cited by 43
Metadata
- Authors
- Fleshner, K., Carlsson, S. V., & Roobol, M. J.
- Venue
- Nature Reviews Urology
- Published
- 2016-12-20
- Volume
- 14
- Issue
- 1
- Pages
- 26-37
- ISSN
- 1759-4812 (ISSN-L)
- 1759-4820
- OpenAlex
- W2566526255
- Cited by
- 219
- References
- 2
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. https://app.cochat.ai/papers/10.1038/nrurol.2016.251
- The paper
- Fleshner, K., Carlsson, S. V., & Roobol, M. J. (2017). The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nature Reviews Urology. https://doi.org/10.1038/nrurol.2016.251
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.